Document:

Exhibit 10.2

 

November 12, 2015

 

 

By Electronic Mail and Facsimile

 

Neurosciences Research Venures, Inc.

364 Patteson Drive, #279

Morgantown, WV 26505

Attention: William Singer

 

Re: Neurotrope, Inc. — PRIVILEGED
AND CONFIDENTIAL 

 

Dear Mr. Singer:

 

In consideration of entering into that certain
Termination and Waiver Agreement, dated November 12, 2015, by and among Neurotrope, Inc. (the “Company”), Neurosciences
Research Ventures, Inc. (“NRV”), Dan Alkon and Northlea Partners LLLP, and for other good and valuable consideration,
the receipt of which is hereby acknowledged, the Company and NRV hereby agree that the Company shall take such reasonable actions
within its control, including calling special board and Nominating and Corporate Governance Committee meetings, so that two (2)
representatives designated by NRV (the “NRV Designees”) are nominated for election to the board of directors (the “Board”)
of the Company at each annual meeting of shareholders until such time as the Amended and Restated License and Services Agreement,
dated February 4, 2015, by and among the Company, Neurotrope Bioscience, Inc., Blanchette Rockefeller Neurosciences Institute and
NRV II, LLC is no longer in effect. The Company agrees to use its best efforts to ensure that (i) each NRV Designee is included
in the Board’s slate of nominees to the stockholders for each election of directors; and (ii) each NRV Designee is included
in the proxy statement prepared by management of the Company in connection with soliciting proxies for every meeting of the stockholders
of the Company called with respect to the election of members of the Board, and at every adjournment or postponement thereof, and
on every action or approval by written consent of the stockholders of the Company or the Board with respect to the election of
members of the Board. Subject to the provisions of applicable law and the rules of any stock exchange on which the Company’s
common stock is listed or quoted, no NRV Designee shall be removed from the Board unless such removal is for cause or requested
in writing by NRV. In the event that any NRV Designee shall cease to serve for any reason, NRV shall be entitled to designate such
person’s successor in accordance with this agreement and the Board shall promptly fill the vacancy with such successor nominee;
it being understood that any such designee shall serve the remainder of the term of the director whom such designee replaces. If
an NRV Designee is not appointed or elected to the Board because of such person’s death, disability, disqualification, withdrawal
as a nominee or for other reason is unavailable or unable to serve on the Board, NRV shall be entitled to designate promptly another
nominee and the director position for which the original NRV Designee was nominated shall not be filled pending such designation.

 

 

[Signature page follows]

 

    	 	 	 

     

    

 

 

Please countersign
this letter in the space provided below and return one copy to the undersigned to reflect NRV’s agreement to the foregoing.

 

	 	Sincerely,	 
	 	 	 
	 	NEUROTROPE,
    INC.	 
	 	 	 
	 	 	 
	 	By:	/s/
    Robert Weinstein	 
	 	Name:	Robert
    Weinstein,	 
	 	Title:	Executive
    Vice President, Chief	 
	 	 	Financial
    Officer, Secretary and Treasurer	 

 

 

ACKNOWLEDGED AND AGREED:

 

NEUROSCIENCES RESEARCH

VENTURES, INC.

 

 

By:_/s/ William Singer___________

Name: William Singer

Title: Director

 

 

    	 	- 2 -Exhibit 10.3

 

Statement of Work Agreement

 

This Statement of Work
Agreement (“SOW Agreement”) is made and entered into on November 12, 2015 by and between Neurotrope Bioscience,
Inc. (“NTRP” or “Neurotrope”) and Blanchette Rockefeller Neurosciences Institute (“BRNI”)
(each, a “Party” and collectively, the “Parties”), and is effective as of November 1, 2015
(the “SOW Agreement Effective Date”), pursuant to that certain Amended and Restated Technology License and Services
Agreement dated February 4, 2015 by and between NTRP, on the one hand, and BRNI and NRV II LLC, on the other hand, (the “TLSA”).
This SOW Agreement hereby incorporates, and is subject to, the terms and conditions of the TLSA. All capitalized terms used herein
but not defined herein shall have the respective meanings ascribed to them in the TLSA.

 

WHEREAS, the
Parties intend that this SOW Agreement shall constitute a Statement of Work pursuant to Paragraphs 3.1 and 3.2 of the TLSA for
Services to be provided by BRNI to NTRP under the TLSA; and

 

WHEREAS pursuant
to Section 5.6 of the TLSA, BRNI has the “sole and exclusive right (but not the obligation) to apply for, file, prosecute,
or maintain patents and applications for the Licensed IP, in each case, in any jurisdiction throughout the world;” and

 

WHEREAS Section
5.6 of the TLSA further provides that “Neurotrope shall reimburse BRNI for all of the attorneys’ fees, translation
costs, filing fees, maintenance fees, and other costs and expenses related to any of the foregoing” (i.e. applications for
filing, prosecution or maintenance) subject to certain provisos; and

 

WHEREAS NTRP
agreed that BRNI should undertake, pursuant to BRNI’s authority from the United States Food and Drug Administration (the
“FDA”), certain limited human compassionate use trials; and

 

    	 	 	 

     

    

 

WHEREAS NTRP
agrees to engage BRNI, pursuant to Section 3.1 and 3.2 of the TLSA, as amended, and this SOW Agreement.

 

NOW THEREFORE,
in consideration of the mutual promises and covenants set forth herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows.

 

		1.	This SOW Agreement shall commence as of the SOW Agreement Effective Date and shall expire on December
31, 2016 (the “SOW Agreement Term”).

 

		2.	NTRP shall pay BRNI one million one hundred sixty six thousand six hundred sixty six dollars ($1,166,666)
in Service Fees payable in the amount of eighty three thousand three hundred thirty three dollars ($83,333) per month for each
month from November 1, 2015 through December 31, 2016. NTRP agrees that the full one million one hundred sixty six thousand six
hundred sixty six dollars ($1,166,666) is a binding obligation of NTRP, and any failure to pay the full amount shall constitute
a breach of TLSA, as amended, and this SOW Agreement. NTRP agrees that the payment for the month of November, 2015 will be paid
by NTRP within two (2) business days after the execution of the Securities Purchase Agreement, dated November 12, 2015, between
Neurotrope and the several buyers thereto

 

		3.	The payments set forth in Paragraph 2 above, as and when made to BRNI, shall also satisfy NTRP’s
obligations to reimburse BRNI pursuant to Section 5.6 of the TLSA for any and all attorneys’ fees, translation costs, filing
fees, maintenance fees, and other costs and expenses related to applying for, filing, prosecuting, and maintaining patents and
applications for the Licensed IP incurred by BRNI during the SOW Agreement Term (but, for the avoidance of doubt, such payments
shall not satisfy any attorneys’ fees, translation costs, filing fees, maintenance fees, or other costs or expenses related
to applying for, filing, prosecuting, and maintaining patents and applications for the Licensed IP incurred by BRNI after the expiration
or termination of the SOW Agreement Term), as well as any litigation costs which BRNI may incur related to any of the Licensed
IP during the SOW Agreement Term. For clarity, BRNI shall not commence any litigation to enforce the Licensed IP without the consent
of NTRP (which consent shall not be unreasonably withheld, delayed, or denied).

 

		4.	BRNI may enroll one (1) additional compassionate use patient, in addition to the compassionate
use patient currently enrolled, in trials of BRNI’s Alzheimer’s (“AD”) therapeutic drug platform
during the SOW Agreement Term, and the payments set forth in Paragraph 2 above, shall satisfy any and all of NTRP’s obligation
whatsoever to BRNI or to any other Third Party for costs incurred or to be incurred by BRNI relating to such trials during the
SOW Agreement Term. However, NTRP and BRNI shall jointly review protocols which shall be established to the parties’ mutual
satisfaction and contain appropriate safety measures to be employed by the treating physician. It is understood and agreed by the
Parties that BRNI may receive cost reimbursement from patients, patients’ families, or other Third Parties in connection
with such enrolled patients and administration of these trials. No additional compassionate use or expanded access patients shall
be enrolled by BRNI without the consent of NTRP.

 

    	 	2	 

     

    

 

		5.	BRNI shall perform the Services requested by NTRP as set forth in Attachment A to this SOW
Agreement, which is incorporated herein and made a part hereof and BRNI’s costs therefore shall be satisfied pursuant to
the payments set forth in Paragraph 2 above.

 

		6.	For the avoidance of doubt, this SOW Agreement shall not waive or modify any of the paragraphs
of the Statement of Work and Account Satisfaction Agreeent between the Parties entered into on February 4, 2015 intended to survive
thereof, namely paragraphs 5, 9, 13, 15, 16, and 19 thereof.

 

 

	Neurotrope Bioscience, Inc.	 	Blanchette Rockefeller Neurosciences Institute
	 	 	 
	By:	/s/ Robert Weinstein	 	By: 	/s/ William
S. Singer
	 	 	 	 	 
	Name: 	Robert Weinstein	 	Name: 	William S. Singer
	 	 	 	 	 
	Title:  	Secretary and Treasurer	 	Title:	 President

 

    	 	3	 

     

    

 

Attachment A

 

Services to be performed
by BRNI’s laboratory will include those to support Neurotrope's ongoing Alzheimer's clinical program through the development
and validation of a new sensitive assay for PKC epsilon levels and activation (pre-clinical work). This assay will then be used
to monitor bryostatin's target engagement in blood samples from patients in Neurotrope's clinical trials. While the new PKC epsilon
assay is being developed, we will use the current assay on those patients enrolled earlier in the Phase 2b trial. The current assay
was able to demonstrate target engagement in the Phase 2a trial. It will also be supplemented with our P32 assay that measures
activation with more sensitivity - before the new assay development is completed."

 

 

 

 

 

    	 	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]